Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study

Baric, Davor; Biocina, Bojan; Unic, Daniel; Sutlic, Zeljko; Rudez, Igor; Vrca, Vesna Bacic; Brkic, Kristina; Ivkovic, Mira
March 2007
European Journal of Cardio-Thoracic Surgery;Mar2007, Vol. 31 Issue 3, p366
Academic Journal
Abstract: Objective: Postoperative bleeding is still one of the most common complications of cardiac surgery. Antifibrinolytic agents successfully reduce bleeding, but there are controversies concerning adverse effects after their systemic use. By topical application of antifibrinolytic agents in pericardial cavity, most of these effects are avoided. We compared the effects of topically applied aprotinin, tranexamic acid and placebo on postoperative bleeding and transfusion requirements. Methods: In this single-center prospective, randomized, double-blind trial, 300 adult cardiac patients were randomized into three groups to receive one million IU of aprotinin (AP group), 2.5g of tranexamic acid (TA group) or placebo (PL group) topically before sternal closure. Groups were comparable with respect to all preoperative and intraoperative variables. Postoperative bleeding, transfusion requirements and hematologic parameters were evaluated. Results: Postoperative bleeding within first 12-h period (AP group 433±294 [350; 360]ml, TA group 391±255 [350; 305]ml, PL group 613±505 [525; 348]ml), as well as cumulative blood loss within 24h (AP group 726±432 [640; 525]ml, TA group 633±343 [545; 335]ml, PL group 903±733 [800; 445]ml), showed statistically significant inter-group differences (both p <0.001). Bleeding rates values were significantly higher in placebo group compared to the groups treated with antifibrinolytic agents (AP and TA groups) concerning both variables. Although TA group showed the lowest values, no statistical differences between TA and AP groups were found. Inter-group difference of blood product requirements was not statistically significant. Conclusions: Topical use of either tranexamic acid or aprotinin efficiently reduces postoperative bleeding. TA seems to be at least as potent as aprotinin, but potentially safer and with better cost-effectiveness ratio.


Related Articles

  • Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial Later, Alexander F.L.; Maas, Jacinta J.; Engbers, Frank H.M.; Versteegh, Michel I.M.; Bruggemans, Eline F.; Dion, Robert A.E.; Klautz, Robert J.M. // European Journal of Cardio-Thoracic Surgery;Aug2009, Vol. 36 Issue 2, p322 

    Abstract: Objective: Tranexamic acid has been suggested to be as effective as aprotinin in reducing blood loss and transfusion requirements after cardiac surgery. Previous studies directly comparing both antifibrinolytics focus on high-risk cardiac surgery patients only or suffer from...

  • Cardiac Surgery and Percutaneous Coronary Interventions in Patients with Hemophilia B: an Overview of Published Reported Cases. Krakow, Elizabeth F.; Ganchev, Ruslan; Anderson, Julia A. M. // Journal of Coagulation Disorders;2009, Vol. 1 Issue 1, p1 

    With an ageing hemophilia population and decreasing mortality from transfusion-transmitted viruses, it is likely that percutaneous coronary interventions and surgery for coronary artery disease and valvular heart disease will become more commonplace. Eighteen reports of cardiac surgery and...

  • The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. Henry, David; Carless, Paul; Fergusson, Dean; Laupacis, Andreas // CMAJ: Canadian Medical Association Journal;1/20/2009, Vol. 180 Issue 2, p183 

    Background: Because of recent concerns about the safety of aprotinin, we updated our 2007 Cochrane review that compared the relative benefits and risks of aprotinin and the lysine analogues tranexamic acid and epsilon aminocaproic acid. Methods: We searched electronic databases, including...

  • Pastures new for cardiac surgery. Crook, Beresford // British Medical Journal;1/21/1978, Vol. 1 Issue 6106, p159 

    Reports on the inadequacy of cardiac surgery services in the Netherlands. Incidence rate of coronary artery disease; Discussions on the proposed transfer of cardiac patients to England for treatment; Details on formal training schemes for cardiac surgeons.

  • Ischaemic Heart Disease.  // Heart;Jul2003, Vol. 89 Issue 7, p815 

    Cites several data related to ischemic heart disease. Prevention of coronary restenosis; Administration of atovastatin; Comparison of the effectiveness of irbesarta to placebo.

  • Does a short course of clarithromycin affect mortality in patients with stable coronary artery disease? Kendall, Claire // CMAJ: Canadian Medical Association Journal;2/28/2006, Vol. 174 Issue 5, p622 

    The article focuses on a study that investigated the role of clarithromycin in the mortality of patients with stable coronary artery disease in Copenhagen, Denmark. The patients were randomly assigned to receive either clarithromycin or placebo for two weeks. The limitations of the study include...

  • Surgical Therapy of Variant Angina Associated with Nonobstructive Coronary Disease. Sussman, Elliot J.; Goldberg, Sheldon; Poll, David S.; Macvaugh III, Horace; Simson, Michael B.; Silber, Steven A.; Kastor, John A. // Annals of Internal Medicine;Jun81, Vol. 94 Issue 6, p771 

    Presents case studies of variant angina associated with nonobstructive coronary disease in two middle-aged men. Information on variant angina; Medical background of the patients; Assessment of the effectiveness of surgical therapy for variant angina.

  • Cardiac operations in patients with hematologic malignancies. Fecher, Alison M.; Birdas, Thomas J.; Haybron, David; Papasavas, Pavlos K.; Evers, Debbie; Caushaj, Philip F. // European Journal of Cardio-Thoracic Surgery;Apr2004, Vol. 25 Issue 4, p537 

    Objectives: Patients with hematologic malignancies are frequently in need of major cardiac operations. Previous reports suggest an increased risk for perioperative complications in these immunodeficient patients. Methods: Patients diagnosed with any type of hematologic malignancy who underwent...

  • Appropriateness of invasive cardiovascular interventions in German hospitals (2000–2001): an evaluation using the RAND appropriateness criteria. Gandjour, Afschin; Neumann, Iris; Wilhelm Lauterbach, Karl // European Journal of Cardio-Thoracic Surgery;Oct2003, Vol. 24 Issue 4, p571 

    Objective: Germany has the highest per capita rate of percutaneous transluminal coronary angioplasties (PTCAs) in Europe and the third highest per capita rate of heart surgeries requiring a heart–lung machine. The goal of this study was to evaluate the appropriateness of PTCA, coronary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics